Abstract
Oncogenic activation of the Ron tyrosine kinase (Macrophage Stimulating Protein receptor) relies on substitutions of two highly conserved residues in the catalytic domain (D1232V and M1254T), which result in ligand-independent activation of the receptor, in vivo tumorigenesis and metastasis. We show here that the Y/F conversion of the Y1317 residue in the kinase domain impairs tumorigenic and metastatic properties of Ron activated by the MEN2B-like mutation (RonM1254T), but not by other two oncogenic substitutions. Furthermore, RonM1254T lacking the multifunctional docking site retains transforming and metastatic activity. These data reveal that the transforming activity of RonM1254T mutant is dependent on Y1317 phosphorylation, suggesting a shift in intramolecular substrate specificity. Consistently, a shift of RonM1254T kinase substrate specificity was observed by in vitro peptide phosphorylation assays and in vivo receptor auto-phosphorylation. The Y1317 phosphorylation elicits by itself activation of PI-3K/Akt and MAPK signalling pathways. Our data indicate that the accomplishment of the full oncogenic phenotype of RonM1254T requires the phosphorylation both of the canonical C-terminal docking site and of the unique Y1317 residue in the tyrosine kinase domain.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bardelli A, Longati P, Gramaglia D, Basilico C, Tamagnone L, Giordano S, Ballinari D, Michieli P and Comoglio PM. . 1998 Proc. Natl. Acad. Sci. USA 95: 14379–14383.
Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SA, Goodfellow PJ and Donis-Keller H. . 1994 Proc. Natl. Acad. Sci. USA 91: 1579–1583.
Gaudino G, Follenzi A, Naldini L, Collesi C, Santoro M, Gallo KA, Godowski PJ and Comoglio PM. . 1994 EMBO J. 13: 3524–3532.
Hanks SK and Quinn AM. . 1991 Methods Enzymol. 200: 38–62.
Iwama A, Yamaguchi N and Suda T. . 1996 EMBO J. 15: 5866–5875.
Jeffers M, Fiscella M, Webb CP, Anver M, Koochekpour S and Vande Woude GF. . 1998 Proc. Natl, Acad. Sci. USA 95: 14417–14422.
Jeffers M and Vande Woude GF. . 1999 Oncogene 18: 5120–5126.
Li BQ, Wang MH, Kung H, Ronsin C, Breathnach R, Leonard EJ and Kamata T. . 1995 Bioch. Bioph. Res. Com. 216: 110–118.
Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, Duffy T, Jabobs P, Tang LH and Modlin I. . 1996 Nat. Genet. 12: 312–314.
Petti LM, Irusta PM and DiMaio D. . 1998 Oncogene 16: 843–851.
Piao X, Paulson R, van der Geer P, Pawson T and Bernstein A. . 1996 Proc. Natl. Acad. Sci. USA 93: 14665–14669.
Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, Graziani A, Panayotou G and Comoglio PM. . 1994 Cell 77: 261–271.
Santoro M, Carlomagno F, Ramano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH and Di Fiore PP. . 1995 Science 267: 381–383.
Santoro MM, Collesi C, Grisendi S, Gaudion G and Comoglio PM. . 1996 Mol. Cell. Biol. 16: 7072–7083.
Santoro MM, Penengo L, Minetto M, Orecchia S, Cilli M and Gaudino G. . 1998 Oncogene 17: 741–749.
Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM and Zbar B . 1997 Nature Genet. 16: 68–73.
Songyang Z and Cantley LC. . 1995 Trends Biol. Sci. 20: 470–475.
Songyang Z, Blechner S, Hoagland N, Hoekstra MF, Piwnica-Worms H and Cantley LC. . 1994 Current Biology 4: 973–982.
Songyang Z, Carraway III KL, Eck MJ, Harrison SC, Feldman RA, Mohammadi M, Schlessinger J, Hubbard SR, Smith DP, Eng C, Lorenzo MJ, Ponder BAJ, Mayer BJ and Cantley LC . 1995 Nature 373: 536–539.
Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, King F, Roberts T, Ratnofsky S and Lechleider RJ . 1993 Cell 72: 767–779.
Stenberg MJE and Gullick WJ. . 1989 Nature 339: 587.
Wang MH, Ronsin C, Gesnel MC, Coupey L, Skeel A, Leonard EJ and Breathnach R. . 1994 Science 266: 117–119.
Wang MH, Montero-Julian FA, Dauny I and Leonard E. . 1996 Oncogene 13: 2167–2175,
Weiner DB, Liu J, Cohen JA, Williams WV and Greene ML. . (1989) Nature 339: 230–231.
Williams TA, Longati P, Pugliese L, Gual P, Bardelli A and Michieli P. . 1999 J. Cell. Physiol. 181: 507–514.
Acknowledgements
This work was supported by research grants from the Associazione Italiana per la Ricerca sul Cancro (AIRC), from CNR ‘Target Project on Biotechnology 99.00373.PF49’ and ‘Co-finanziamento MURST’.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Santoro, M., Penengo, L., Orecchia, S. et al. The Ron oncogenic activity induced by the MEN2B-like substitution overcomes the requirement for the multifunctional docking site. Oncogene 19, 5208–5211 (2000). https://doi.org/10.1038/sj.onc.1203819
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203819
Keywords
This article is cited by
-
Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160
Journal of Experimental & Clinical Cancer Research (2008)
-
Molecular targets in cancer therapy: the Ron approach
Oncology Reviews (2008)